Boyle Dana sold $644K of LQDA

Boyle Dana (Chief Accounting Officer) sold 9,002 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.64M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boyle Dana
Published Jul 14, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The only new information is the disclosed sale details and that it was executed under a pre-arranged 10b5-1 plan, which generally reduces interpretive value.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not disclose any concurrent corporate event, earnings timing, or changes in guidance; the sale size is moderate relative to typical institutional flows.

Relevance 4/10Novelty 3/10Timing: After-hours/filing update on July 14 for a July 13 insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by CFO Boyle Dana.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp insider Form 4 shows CFO Boyle Dana sold 9,002 shares in open-market trades totaling about $643.7K on July 13.

Expected impact

Likely minimal impact on the stock price; any effect is typically short-lived and outweighed by broader catalysts.

Evidence & confidence

The filing is a disclosed open-market sale by an accounting officer, explicitly under a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced confidence, so traders may watch for follow-on insider activity or changes in trading patterns.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Boyle Dana

    Chief Accounting Officer who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.